Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
ENVB
Enveric Biosciences, Inc.
Enveric Biosciences, Inc. (ENVB) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Profitability (D+).
Quantitative Factor Evaluation • Updated
Overall Rating
2.5
/ 5.0
C+
Value
B+
Factor Score
3.7
/ 5.0
Growth
C+
Factor Score
2.5
/ 5.0
Profitability
D+
Factor Score
1.7
/ 5.0
Momentum
C-
Factor Score
2.1
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-1.1
EV / EBITDA
0.2
Rev Growth YoY
N/A
Gross Margin
0.0%
Price Return 3M
-2.6%
Price Return 12M
-75.3%
Catalyst Signal
0.00
Market Cap
$6.8M
TTM Revenue
N/A
Price / Sales
N/A
ROE
-170.0%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | B+ (3.7) | C+ (2.5) | D+ (1.7) | C- (2.1) | C+ (2.6) | C+ (2.5) |
| 2026-11-04 | B+ (3.7) | C+ (2.5) | D+ (1.7) | D+ (1.8) | C+ (2.7) | C (2.5) |
| 2026-10-28 | B+ (3.7) | C+ (2.5) | D+ (1.7) | D+ (1.8) | C+ (2.7) | C (2.5) |
| 2026-10-21 | B+ (3.7) | C+ (2.5) | D+ (1.7) | C- (1.9) | C+ (2.6) | C (2.5) |
| 2026-10-14 | B+ (3.7) | C+ (2.5) | D+ (1.7) | C (2.3) | C+ (2.6) | C+ (2.6) |
Page
1
of
4